Renaissance Technologies LLC has recently announced that it has increased stake in Heat Biologics Inc. (NASDAQ:HTBX) by 68.58%. After grabbing 3.03 million shares, the institutional investor is now in possession of 1.23 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.26% having worth around $6.58 million. Moreover, Magnus Financial Group LLC increased its share by 0.81 million to have a control over 2.25 million shares. And The Vanguard Group, Inc. raised its holdings to 96518.0 shares by acquiring 2.19 million shares or 1.64% of the stake.
Heat Biologics Inc. (HTBX) concluded trading on 08/27/20 at a closing price of $1.24, with 9.77 million shares of worth about $12.11 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -10.79% during that period and on Thursday the price saw a loss of about -7.46%. Currently the company’s common shares owned by public are about 87.93M shares, out of which, 75.53M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 3 analysts are covering the HTBX stock and their offered price forecasts bring an average price target of $5.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $5.00 and could fall to a lowest price of $5.00. Analysts also issued an outlook of 2.00 for the Heat Biologics Inc. stock for next 12 months. However, touching the estimated high of $5.00 would mean a gain of 75.2% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 4 times over the past 12 months. They bought 1,315,625 shares in 3 of the transactions. In 1 selling transactions, insiders dumped 4,440 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Heat Biologics Inc. Vanguard Total Stock Market Index is currently holding 2.0 million shares of worth totaling $4.34 million. The company recently came buying 0.72 million shares which brought its stake up to 1.49% of the company’s outstanding shares. Vanguard Extended Market Index Fu bought 0.27 million shares, after which its hold over company’s outstanding shares expand to 0.80%, leaving 1.07 million shares with the mutual fund that have a worth of about $2.33 million. Fidelity Extended Market Index Fu, after selling 0.25 million shares, have now control over 0.19% of the stake in the company. It holds -0.16 million shares of worth $0.54 million.
Heat Biologics Inc. (NASDAQ: HTBX) started trading at $1.23, below -$0.11 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $1.24, or with a loss of -7.46%. Stock saw a price change of -10.79% in past 5 days and over the past one month there was a price change of -44.39%. Year-to-date (YTD), HTBX shares are showing a performance of 161.05% which increased to 134.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.19 but also hit the highest price of $4.30 during that period. While comparing its average daily trading volume of 31.83 million shares, we see that about 9.77 million changed hands on the day. The stock is currently trading -30.32% below its 20-day simple moving average (SMA20), while that difference is down -22.19% for SMA50 and it goes to 56.67% higher than SMA200.
Renaissance Technologies LLC acquired 3.03 million shares of Heat Biologics Inc. having value of about $6.58 million. Data submitted at the U.S SEC by Renaissance Technologies LLC revealed that the firm now holds 1.23 million shares in the company valued at close to $1529530.08, or have control over 68.58% stake in the company. Heat Biologics Inc. (NASDAQ: HTBX) currently have 87.93M outstanding shares and institutions hold larger chunk of about 13.00% of that. Holding of mutual funds in the company is about 3.36% while other institutional holders and individual stake holders have control over 5.19% and 2.63% of the stake respectively.
The stock has a current market capitalization of $185.55M and its 3Y-monthly beta is at 0.60. It has posted earnings per share of -$0.45 in the same period. It has Quick Ratio of 7.70 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HTBX, volatility over the week remained 12.66% while standing at 10.87% over the month.
Analysts are in expectations that Heat Biologics Inc. (HTBX) stock would likely to be making an EPS of -$0.03 in the current quarter, while forecast for next quarter ESPS is -$0.04 and it is -$0.24 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.03 which is -$0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.18 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 33.20% while it is estimated to decrease by 0.00% in next year.
Analysts at 3 brokerage firms have issued recommendations for the Heat Biologics Inc. (HTBX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 3 Wall Street analysts, 3 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on June 20, 2016 offering a Buy rating for the stock and assigned a target price of to it. Coverage by Noble Financial stated Heat Biologics Inc. (HTBX) stock as a Buy in their note to investors on January 08, 2016, suggesting a price target of $16 for the stock. On May 26, 2015, H.C. Wainwright Initiated their recommendations, while on September 18, 2013, Aegis Capital Initiated their ratings for the stock with a price target of $36.